ライフサイエンスコーパス: hydrochlorothiazide

1 and 1 was the combination of triamterene and hydrochlorothiazide.

2 and equally reduced with both isradipine and hydrochlorothiazide.

3 determined at baseline and after 9 weeks of hydrochlorothiazide.

4 as it is superior to normally used doses of hydrochlorothiazide.

5 adverse cardiovascular events or deaths than hydrochlorothiazide.

6 lus amlodipine compared with benazepril plus hydrochlorothiazide.

7 enazepril plus amlodipine or benazepril plus hydrochlorothiazide.

8 eived either 50 mg of atenolol or 12.5 mg of hydrochlorothiazide.

9 g trandolapril; and 3430 (43.7%) were taking hydrochlorothiazide.

10 At week 8, hydrochlorothiazide 12.5 to 25 mg and/or amlodipine 10 m

11 cebo and to candesartan (16 mg per day) plus hydrochlorothiazide (12.5 mg per day) or placebo.

12 g per day), candesartan (16 mg per day), and hydrochlorothiazide (12.5 mg per day) was associated wit

13 ne (5 mg; n=5744) or benazepril (20 mg) plus hydrochlorothiazide (12.5 mg; n=5762), orally once daily

14 ce daily doses of isradipine (2.5-5.0 mg) or hydrochlorothiazide (12.5-25 mg).

15 GITS) formulation (n=3157), or co-amilozide (hydrochlorothiazide 25 mg [corrected] plus amiloride 2.5

16 Hydrochlorothiazide, 25 mg twice daily, for a mean (+/-

17 dralazine 7.5 mg/d, reserpine 0.15 mg/d, and hydrochlorothiazide 3 mg/d [HRH]) during weeks 7 through

18 atients required supplemental treatment with hydrochlorothiazide (59% versus 34%, P<0.001) but not at

19 ose (irbesartan 37.5 mg, amlodipine 1.25 mg, hydrochlorothiazide 6.25 mg, and atenolol 12.5 mg).

20 lodipine, 189 of 561, 33.7%; benazepril plus hydrochlorothiazide, 85 of 532, 16.0%).

21 the COER verapamil (99/277) and atenolol or hydrochlorothiazide (88/274) groups; HR, 1.15 (95% CI, 0

22 es were 82%, 78%, and 14%, respectively, for hydrochlorothiazide; 88%, 67%, and 40%, respectively, fo

23 Hydrochlorothiazide, a blocker of the Na(+)-Cl(-) cotran

24 s, and bone mineral density before and after hydrochlorothiazide administration.

25 lorothiazide, or 5 mg amiloride plus 12.5 mg hydrochlorothiazide; all doses were doubled after 12 wee

26 Moreover, hydrochlorothiazide, an NCC-blocking drug, reversed tacr

27 ups, and mean SBP decreased by 19.5 mm Hg in hydrochlorothiazide and 16.0 mm Hg in isradipine (P=.002

28 Open-label hydrochlorothiazide and a dihydropyridine calcium antago

29 while MSNA responses were different between hydrochlorothiazide and aliskiren (P = 0.006 pre/post x

30 ance test (OGTT), compared first between the hydrochlorothiazide and amiloride groups, and then betwe

31 l or long-acting nifedipine, plus adjunctive hydrochlorothiazide and atenolol when needed to control

32 rates were similar with both benazepril and hydrochlorothiazide and benazepril and amlodipine, but r

33 e and amiloride groups, and then between the hydrochlorothiazide and combination groups.

34 tihypertensive treatment with losartan, plus hydrochlorothiazide and other medications when needed fo

35 Hydrochlorothiazide and prazosin were best in low- and m

36 mediate release compartment with aspirin and hydrochlorothiazide and three sustained release compartm

37 ho were newly treated with chlorthalidone or hydrochlorothiazide and were not hospitalized for heart

38 er, 1 was the combination of triamterene and hydrochlorothiazide, and 1 an alpha-blocker.

39 were randomly assigned to amiloride, 146 to hydrochlorothiazide, and 150 to the combination group.

40 dequate blood pressure control on captopril, hydrochlorothiazide, and atenolol show a reduction of LV

41 re taking atenolol; 4733 (60.3%) were taking hydrochlorothiazide; and 4113 (52.4%) were taking trando

42 il) or beta-blocker/diuretic-based (atenolol/hydrochlorothiazide) antihypertensive care strategy.

43 Calcium channel blockers and hydrochlorothiazide are important causes of pruritic ski

44 osartan (n = 660) or atenolol (n = 666) with hydrochlorothiazide as the second agent in both arms, fo

45 candesartan at a dose of 16 mg per day plus hydrochlorothiazide at a dose of 12.5 mg per day or plac

46 candesartan at a dose of 16 mg per day plus hydrochlorothiazide at a dose of 12.5 mg per day was not

47 The combination of amiloride with hydrochlorothiazide, at doses equipotent on blood pressu

48 domization to 1 of 6 antihypertensive drugs: hydrochlorothiazide, atenolol, captopril, clonidine, dil

49 eft atrial size decreased significantly with hydrochlorothiazide, atenolol, clonidine, and diltiazem

50 enazepril, combined with amlodipine (B+A) or hydrochlorothiazide (B+H).

51 was as clinically effective as the atenolol-hydrochlorothiazide-based strategy in hypertensive CAD p

52 Hydrochlorothiazide (BCS class IV drug) was chosen as th

53 phisms tested, that has been associated with hydrochlorothiazide BP response.

54 The genetic score of the hydrochlorothiazide BP-lowering alleles was associated w

55 +/- 3.3-mm reduction of LV cavity size with hydrochlorothiazide but no reduction with isradipine.

56 de derivatives (IDRA-21, hydroflumethiazide, hydrochlorothiazide, chlorothiazide, trichlormethiazide,

57 e combination was superior to the benazepril-hydrochlorothiazide combination in reducing cardiovascul

58 ignificantly higher in 25 good responders to hydrochlorothiazide compared with 25 poor responders (P=

59 enhanced removal of atorvastatin-diclofenac-hydrochlorothiazide (during the whole treatment) and ran

60 The superior efficacy of hydrochlorothiazide for LV mass reduction is associated

61 gests that chlorthalidone may be superior to hydrochlorothiazide for the treatment of hypertension.

62 93) and in the combination group than in the hydrochlorothiazide group (-0.42 mmol/L [-0.84 to -0.004

63 ipine group (9.6%) and 679 in the benazepril-hydrochlorothiazide group (11.8%), representing an absol

64 (81.6% to 89.7%) except men in the high-dose hydrochlorothiazide group (60.5%).

65 e COER verapamil group vs 365 in atenolol or hydrochlorothiazide group (hazard ratio [HR], 1.02; 95%

66 pared with 215 (3.7%) in the benazepril plus hydrochlorothiazide group (HR 0.52, 0.41-0.65, p<0.0001)

67 tly lower in the amiloride group than in the hydrochlorothiazide group (mean difference -0.55 mmol/L

68 roup (n = 118) compared with the atenolol or hydrochlorothiazide group (n = 79) (HR, 1.54 [95% CI, 1.

69 +/- 41 g lower than that at baseline in the hydrochlorothiazide group (p = 0.003) but only 7 +/- 50

70 p was significantly greater than that in the hydrochlorothiazide group (p=0.0068).

71 oint (95% CI, -0.12 to 1.71) for the 12.5-mg hydrochlorothiazide group and 0.92 percentage point (CI,

72 pine was significantly greater for the 25-mg hydrochlorothiazide group at 6 months (intergroup differ

73 on were more frequent in the benazepril plus hydrochlorothiazide group than in the benazepril plus am

74 ticipants in the amiloride group, 134 in the hydrochlorothiazide group, and 133 in the combination gr

75 amlodipine group than in the benazepril plus hydrochlorothiazide group.

76 group and 132.5/74.4 mm Hg in the benazepril-hydrochlorothiazide group.

77 for partcipants assigned to the atenolol or hydrochlorothiazide group.

78 ffer significantly between the amiloride and hydrochlorothiazide groups, but the fall in blood pressu

79 ges in intracellular Ca2+ concentration, but hydrochlorothiazide had no effect.

80 Animals given the hydrochlorothiazide had the highest urinary volume, but

81 d to add-on therapy of spironolactone 25 mg, hydrochlorothiazide (HCTZ) 12.5 mg, or placebo for 6 mon

82 to evaluate the antihypertensive efficacy of hydrochlorothiazide (HCTZ) by ambulatory blood pressure

83 Hydrochlorothiazide (HCTZ) in the 12.5-mg dose remains t

84 from 25 responders and 25 non-responders to hydrochlorothiazide (HCTZ) or chlorthalidone.

85 sive drugs (TRX; reserpine, hydralazine, and hydrochlorothiazide in drinking water; SP+TRX, n = 7) or

86 on, support first-line use of amiloride plus hydrochlorothiazide in hypertensive patients who need tr

87 s amlodipine was superior to benazepril plus hydrochlorothiazide in reducing cardiovascular morbidity

88 Hydrochlorothiazide increases urine volume without enhan

89 on of diastolic BP, 6 months of therapy with hydrochlorothiazide is associated with a substantial red

90 patients receiving isradipine compared with hydrochlorothiazide is of concern and should be studied

91 tertile of pretreatment LV mass treated with hydrochlorothiazide (mean, -42.9; 95% confidence limits,

92 f these loci with BP response to atenolol or hydrochlorothiazide monotherapy in 768 hypertensive part

93 inhibitor, aliskiren (n = 7), or a diuretic, hydrochlorothiazide (n = 7), for 6 months.

94 sudden death) in isradipine (n=25; 5.65%) vs hydrochlorothiazide (n=14; 3.17%) (P=.07), and a signifi

95 bypass graft) in isradipine (n=40; 9.05%) vs hydrochlorothiazide (n=23; 5.22%) (P=.02).

96 epril plus amlodipine, n=70; benazepril plus hydrochlorothiazide, n=73).

97 while upright aldosterone was greater after hydrochlorothiazide only (P = 0.002).

98 e-pill combinations of either benazepril and hydrochlorothiazide or benazepril and amlodipine.

99 g simvastatin, 10 mg lisinopril, and 12.5 mg hydrochlorothiazide or to usual care (n=1002).

100 ent strategy on the basis of either atenolol/hydrochlorothiazide or verapamil-SR (sustained release)/

101 ith starting doses of 10 mg amiloride, 25 mg hydrochlorothiazide, or 5 mg amiloride plus 12.5 mg hydr

102 h atenolol, captopril, clonidine, diltiazem, hydrochlorothiazide, or prazosin in a double-masked tria

103 h atenolol, captopril, clonidine, diltiazem, hydrochlorothiazide, or prazosin in a double-masked tria

104 n of mean maximum IMT between isradipine and hydrochlorothiazide over 3 years (P=.68).

105 concentration in lake water was observed for hydrochlorothiazide (over a factor of 10), and this was

106 decreased by 43 +/- 45 g (mean +/- SD) with hydrochlorothiazide (p < 0.001) but only by 11 +/- 48 g

107 mm Hg at 3 and 6 months, respectively, with hydrochlorothiazide (p = 0.003, between-group comparison

108 ring alleles was associated with response to hydrochlorothiazide (P=0.0006 for systolic BP; P=0.0003

109 ent to one of three study groups: 12.5 mg of hydrochlorothiazide per day, 25 mg of hydrochlorothiazid

110 mg of hydrochlorothiazide per day, 25 mg of hydrochlorothiazide per day, or placebo.

111 with those prescribed 12.5, 25, or 50 mg of hydrochlorothiazide per day, the former were more likely

112 In healthy older adults, low-dose hydrochlorothiazide preserves bone mineral density at th

113 malization by treatment with hydralazine and hydrochlorothiazide prevented angiotensin II-induced vas

114 vents per 100 person-years of follow-up, and hydrochlorothiazide recipients experienced 3.4 events pe

115 orthalidone recipient was matched to up to 2 hydrochlorothiazide recipients on the basis of age, sex,

116 ) being treated with a hydralazine-reserpine-hydrochlorothiazide regimen.

117 Hydrochlorothiazide resolved hypercalciuria and increase

118 , (2) RSG + furosemide (RSG+FRUS), (3) RSG + hydrochlorothiazide (RSG+HCTZ), (4) RSG + spironolactone

119 considered in preference to benazepril plus hydrochlorothiazide since it slows progression of nephro

120 -3.3 mm) in left atrial size at 2 years with hydrochlorothiazide than with any other drug.

121 wever, reduction at 2 years was greater with hydrochlorothiazide than with captopril or prazosin.

122 ate, climbazole, diclofenac, furosemide, and hydrochlorothiazide), the measured persistence was lower

123 In patients allocated benazepril and hydrochlorothiazide, the primary endpoint (per 1000 pati

124 NDINGS: In patients allocated benazepril and hydrochlorothiazide, the primary endpoint (per 1000 pati

125 es were randomized to isradipine (n = 89) or hydrochlorothiazide therapy (n = 45).

126 diltiazem for older black men, from 70% for hydrochlorothiazide to 92% for atenolol for younger whit

127 olol for younger white men, and from 84% for hydrochlorothiazide to 95% for diltiazem for older white

128 the following conditions: normal, hydrated, hydrochlorothiazide treated and phlorizin treated.

129 supine and upright MSNA became greater after hydrochlorothiazide treatment (supine, 72 +/- 18 post vs

130 Hydrochlorothiazide treatment in hypercalciuric and oste

131 le was associated with better BP response to hydrochlorothiazide versus noncarriers (Delta systolic B

132 Trandolapril and/or hydrochlorothiazide was administered to achieve blood pr

133 Without adjustment for covariates, only hydrochlorothiazide was associated with decreases in lef

134 Hydrochlorothiazide was associated with greater overall

135 Greater LV mass reduction with hydrochlorothiazide was related to a 2.8 +/- 3.3-mm redu

136 ystem blocker with amlodipine, compared with hydrochlorothiazide, was superior in reducing cardiovasc

137 Trandolapril and hydrochlorothiazide were used as added agents.

138 dies may predict BP response to atenolol and hydrochlorothiazide when assessed through risk scoring.